ReCode Therapeutics Stock

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.

Sign up today and learn more about ReCode Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About ReCode Therapeutics Stock

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics. Its selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

Funding History

February 2019$2.0M
March 2020$80.0M
October 2021$260M
June 2022$120M
January 2023$10.0M
September 2023$50.0M

Management

Co-Founder

Daniel Siegwart

Co-Founder

Philip Thomas

CEO & Board Member

Shehnaaz Suliman

Senior Vice President and Head of Business Development

Angele Maki

Senior Vice President of Clinical Development

Nicholas P. France

Senior Vice President of Clinical Development

John Matthews

President & CSO

David Lockhart

Board Member

Rana Al-Hallaq

Board Member

Helen S. Kim

Board of Directors

Kouki Harasaki

Board Member

David Lockhart

Board Member

Michael Torres

Board of Directors

Shehnaaz Suliman

Board Member

Peter Thompson

Board of Directors

Rakhshita Dhar

Board Member

Ed Hurwitz

Board of Directors

Alan Colowick

Board Member

Oleg Nodelman

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo